Literature DB >> 25987985

Preclinical mouse models of osteosarcoma.

Özge Uluçkan1, Aude Segaliny2, Sander Botter3, Janice M Santiago4, Anthony J Mutsaers5.   

Abstract

Osteosarcoma is the most common form of primary bone tumors with high prevalence in children. Survival rates of osteosarcoma are low, especially in the case of metastases. Mouse models of this disease have been very valuable in investigation of mechanisms of tumorigenesis, metastasis, as well as testing possible therapeutic options. In this chapter, we summarize currently available mouse models for osteosarcoma and provide detailed methodology for the isolation of cell lines from genetically engineered mouse models (GEMMs), gene modification and tumor cell injection methods, as well as imaging techniques.

Entities:  

Year:  2015        PMID: 25987985      PMCID: PMC4422092          DOI: 10.1038/bonekey.2015.37

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  25 in total

1.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.

Authors:  Francois Lamoureux; Peggy Richard; Yohann Wittrant; Séverine Battaglia; Paul Pilet; Valérie Trichet; Frédéric Blanchard; Francois Gouin; Bruno Pitard; Dominique Heymann; Francoise Redini
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Fluorescence-guided surgery improves outcome in an orthotopic osteosarcoma nude-mouse model.

Authors:  Shinji Miwa; Yukihiko Hiroshima; Shuya Yano; Yong Zhang; Yasunori Matsumoto; Fuminari Uehara; Mako Yamamoto; Hiroaki Kimura; Katsuhiro Hayashi; Michael Bouvet; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  J Orthop Res       Date:  2014-08-19       Impact factor: 3.494

3.  Longitudinal assessment of lung cancer progression in the mouse using in vivo micro-CT imaging.

Authors:  Eman Namati; Jacqueline Thiesse; Jessica C Sieren; Alan Ross; Eric A Hoffman; Geoffrey McLennan
Journal:  Med Phys       Date:  2010-09       Impact factor: 4.071

4.  Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease.

Authors:  Natacha Entz-Werlé; Philippe Choquet; Agnès Neuville; Sabine Kuchler-Bopp; François Clauss; Jean-Marc Danse; Pauline Simo-Noumbissie; Eric Guérin; Marie-Pierre Gaub; Jean-Noel Freund; Nelly Boehm; André Constantinesco; Patrick Lutz; Dominique Guenot; Fabienne Perrin-Schmitt
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

5.  Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Authors:  Sam D Molyneux; Marco A Di Grappa; Alexander G Beristain; Trevor D McKee; Daniel H Wai; Jana Paderova; Meenakshi Kashyap; Pingzhao Hu; Tamara Maiuri; Swami R Narala; Vuk Stambolic; Jeremy Squire; Josef Penninger; Otto Sanchez; Timothy J Triche; Geoffrey A Wood; Lawrence S Kirschner; Rama Khokha
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

6.  BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.

Authors:  Bérengère Gobin; Marc Baud' Huin; François Lamoureux; Benjamin Ory; Céline Charrier; Rachel Lanel; Séverine Battaglia; Françoise Redini; Frédéric Lezot; Frédéric Blanchard; Dominique Heymann
Journal:  Int J Cancer       Date:  2014-06-30       Impact factor: 7.396

7.  Notch activation as a driver of osteogenic sarcoma.

Authors:  Jianning Tao; Ming-Ming Jiang; Lichun Jiang; Jason S Salvo; Huan-Chang Zeng; Brian Dawson; Terry K Bertin; Pulivarthi H Rao; Rui Chen; Lawrence A Donehower; Francis Gannon; Brendan H Lee
Journal:  Cancer Cell       Date:  2014-09-08       Impact factor: 31.743

8.  A meta-analysis of osteosarcoma outcomes in the modern medical era.

Authors:  Daniel C Allison; Scott C Carney; Elke R Ahlmann; Andrew Hendifar; Sant Chawla; Alex Fedenko; Constance Angeles; Lawrence R Menendez
Journal:  Sarcoma       Date:  2012-03-18

9.  Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging.

Authors:  Marleen Keyaerts; Isabel Remory; Vicky Caveliers; Karine Breckpot; Tomas J Bos; Jan Poelaert; Axel Bossuyt; Tony Lahoutte
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

10.  In vivo bioluminescent imaging of mammary tumors using IVIS spectrum.

Authors:  Ed Lim; Kshitij D Modi; Jaebeom Kim
Journal:  J Vis Exp       Date:  2009-04-29       Impact factor: 1.355

View more
  14 in total

Review 1.  Tissue engineered models of healthy and malignant human bone marrow.

Authors:  Alan Chramiec; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2019-04-17       Impact factor: 15.470

Review 2.  Role of animal models in biomedical research: a review.

Authors:  P Mukherjee; S Roy; D Ghosh; S K Nandi
Journal:  Lab Anim Res       Date:  2022-07-01

3.  Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.

Authors:  Vincent Crenn; Kevin Biteau; Jérôme Amiaud; Clotilde Dumars; Romain Guiho; Luciano Vidal; Louis-Romée Le Nail; Dominique Heymann; Anne Moreau; François Gouin; Françoise Redini
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

4.  Editorial: A Novel Monoclonal Antibody-Targeting Angiogenesis by Inhibiting Secreted Frizzled-Related Protein 2.

Authors:  Julie E Lang; William W Tseng; Irene Kang
Journal:  Ann Surg Oncol       Date:  2019-09-09       Impact factor: 4.339

Review 5.  Biology of Bone Sarcomas and New Therapeutic Developments.

Authors:  Hannah K Brown; Kristina Schiavone; François Gouin; Marie-Françoise Heymann; Dominique Heymann
Journal:  Calcif Tissue Int       Date:  2017-12-13       Impact factor: 4.333

6.  Jaw osteosarcoma models in mice: first description.

Authors:  Hélios Bertin; Romain Guilho; Régis Brion; Jérôme Amiaud; Séverine Battaglia; Anne Moreau; Anne Brouchet-Gomez; Julie Longis; Benoit Piot; Dominique Heymann; Pierre Corre; Françoise Rédini
Journal:  J Transl Med       Date:  2019-02-27       Impact factor: 5.531

7.  Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation.

Authors:  Yujiao Han; Heng Feng; Jun Sun; Xiaoting Liang; Zhuo Wang; Wenhui Xing; Qinggang Dai; Yang Yang; Anjia Han; Zhanying Wei; Qing Bi; Hongbin Ji; Tiebang Kang; Weiguo Zou
Journal:  J Clin Invest       Date:  2019-02-26       Impact factor: 14.808

8.  Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma.

Authors:  Tracy A Marko; Ghaidan A Shamsan; Elizabeth N Edwards; Paige E Hazelton; Susan K Rathe; Ingrid Cornax; Paula R Overn; Jyotika Varshney; Brandon J Diessner; Branden S Moriarity; M Gerard O'Sullivan; David J Odde; David A Largaespada
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379

9.  Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice.

Authors:  Maria Eugenia Marques da Costa; Estelle Daudigeos-Dubus; Anne Gomez-Brouchet; Olivia Bawa; Valerie Rouffiac; Massimo Serra; Katia Scotlandi; Conceição Santos; Birgit Geoerger; Nathalie Gaspar
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

Review 10.  Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies.

Authors:  Hongmei Xiao; Peter E Jensen; Xinjian Chen
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.